Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + oxaliplatin + S-1
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Tislelizumab + oxaliplatin + S-1 is an investigational perioperative and neoadjuvant chemoimmunotherapy regimen for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma. Tislelizumab is a humanized anti-programmed cell death protein 1 monoclonal antibody that restores antitumor T-cell activity by blocking PD-1 checkpoint signaling. Oxaliplatin is a platinum chemotherapy agent that forms cytotoxic DNA crosslinks. S-1 is an oral fluoropyrimidine fixed-dose combination of tegafur, gimeracil, and oteracil; tegafur is converted to 5-fluorouracil, gimeracil inhibits dihydropyrimidine dehydrogenase to increase 5-fluorouracil exposure, and oteracil reduces gastrointestinal activation of 5-fluorouracil. The regimen is commonly referred to as tislelizumab plus SOX, where SOX denotes S-1 plus oxaliplatin.
- Other names
- SOX + tislelizumabtislelizumab + S-1 + oxaliplatintislelizumab + SOXtislelizumab + oxaliplatin + S-1tislelizumab + oxaliplatin + tegafur + gimeracil + oteraciltirelizumab + oxaliplatin + S-1
02
Targets
TS (Thymidylate synthase)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + oxaliplatin + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + oxaliplatin + S-1.